PARP Inhibitor Olaparib and Its Combination Therapy in Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-analysis.

ABSTRACT:

Background and objective

Olaparib is one of the earliest approved treatment options for metastatic castration-resistant prostate cancer (mCRPC). This systematic review and network meta-analysis aimed to determine the optimal olaparib strategy for treating mCRPC.

Methods

The Cochrane, Embase, PubMed, and Web of Science databases were searched comprehensively using "mCRPC" and "olaparib" as keywords. Study quality was appraised with the National Institutes of Health tools. Data were analyzed in R version 4.4.1. The primary endpoints included progression-free (PFS) and overall (OS) survival. The secondary endpoints included adverse events and severe adverse events (grade ≥3). Effect sizes were reported as hazard ratios (HRs) and risk ratios, with 95% credibility intervals (CrIs

SUBMITTER: Li Y 

PROVIDER: S-EPMC12804617 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature